Exelixis: Substantial Unlocked Value In The Cabozantinib Franchises

Jun. 06, 2017 7:55 AM ETExelixis, Inc. (EXEL)JAZZ, PLX41 Comments

Summary

  • By inhibiting multiple targets simultaneously, the anti-cancer molecule cabozantinib is showing stellar efficacy and safety in treating various cancer types.
  • While procuring meaningful revenues, the development of cabozantinib for a vast number of cancer indications ensures strong future sales growth.
  • Most of the clinical trials studying cabozantinib will highly likely post positive future results.
  • Despite the recent run-up in share price, there are substantial values to be unlocked in the aforesaid tyrosine kinases inhibitor.

As part of the biotech bull run that commenced in late 2016, Exelixis, Inc. (NASDAQ:EXEL) rewarded shareholders with more than four-folds appreciation in share price for the past year. Based in San Francisco, California, the firm is focusing on the development and commercialization of molecules to improve the outcome and care for patients afflicted by cancers. While it is seemingly the market sentiment that share price is trading at a premium, our analytical research proved otherwise. There is substantial unlocked value in the cabozantinib franchises that, in and of itself, ensures aggressive future sales growth. And, despite that the company has a highly enriched pipeline, we shall evaluate the prospects of cabozantinib alone in this research.

Source: Google Finance

In 2012, cabozantinib received its first U.S. FDA approval for the treatment of progressive, metastatic medullary thyroid cancer under the brand Cometriq®. Moreover, the said molecule gained further approval as Cabometyx® on April 25, 2016, to manage patients afflicted with advanced renal cell carcinoma, who had undergone prior (angiogenic) treatment.

Cabozantinib's Mechanism of Action

Usually, a patient who is put on the cancer treatment coined chemotherapy would show improved responses and only be disappointed when their cancer comes back due to drug resistance. Among the various anti-cancer drugs, cabozantinib strongly differentiates itself due to having the specialized mechanism of action. Instead of attacking a single target (like a monoclonal antibody), the said drug works by simultaneously inhibiting different kinases (MET, AXL, VEGF receptors, and RET) involved in the disease processes (including oncogenesis, metastasis, tumor angiogenesis, drug resistance, and the maintenance of tumor environment).

Research proved that the inhibition of multiple targets (as well as the application of combination therapies) is better at preventing cancer relapses than conventional treatment alone. In addition, the aforementioned approach ensures the optimized efficacy and safety due to drug-target specificity. With

This article was written by

BioSci Capital Partners profile picture
15.68K Followers
Become an Expert Bio-Investor with the Columbia Doc/Scientist/Market Whiz

Founded by Dr. Harvey Tran MD, MS, CNPR, (in collaboration with other PhDs), Integrated BioSci Investing LLC (“IBI) is a growing community of experts and everyday investors who help one another to invest better.

We bring to you a NEW investment philosophy called “Integrated BioSci Investing.” It's a distillation of value/growth investing wisdom from gurus such as Warren Buffett, Buffet's mentors (Ben Graham and Phil Fischer), and Sir John Templeton that are adapted specifically for biotech stocks.

IBI's analytical research is powered by the integration of (medical, scientific, and market) expertise to deliver unprecedented accuracy in clinical trial forecasting that, in and of itself, is one of the requisites to finding alpha bioscience investment.

Ultimately, our tireless due diligence and the wisdom of IBI members translate into strong returns for you. To name a couple of winners, Crispr Therapeutics (CRSP), CryoPort (CYRX), and Guardant Health (GH), correspondingly delivered 679.1%, 778.3%, and +435.9% for our subscribers."

As an IBI member, you’ll enjoy the following EXCLUSIVE benefits: daily real-time research articles that are comprehensive and more in-depth than free research articles; access to the chat room with many experts and everyday investors for you to ask your questions live about your favorite stocks (you’re expected to get an answer no later than 24 hours); ability to view our high performing portfolios and their pertinent updates; consulting on strategies to help you set up your own portfolios; Our best ideas and their updates via a research article or chat; potential to have research featured on your favorite companies; ability to reach Dr. Tran via phone call or Skype as you wish.

CLICK the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs.

CONNECT with Dr. Tran through his LinkedTree https://linktr.ee/DrHarveyTran

READ more on www.drtranbiosci.com (and make sure to register for our mailing list).

LEARN about Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html

"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (41)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.